Original Articles
Rachna Mishra
Abstract
The efficacy of delavirdine was found to be lower than other FDA approved NNRTIs, therefore, the US department of health and Human Services recommended its use not as a part of initial therapy but in combination with other drugs. The molecular assemblage of delavirdine was concurrently also altered by rearranging its vital fragments into altogether a different molecular setting and by synthesized enone ester formation of new delavirdine analogue could be possible.